Moreover, the FXR agonist obeticholic acid shows significant benefit in phase 3 interim results and remains the candidate for first conditional approval as a NASH therapeutic [316]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.